Exercise testing in nonatherosclerotic heart disease: hypertrophic cardiomyopathy, valvular heart disease, and arrhythmias.

摘要

Exercise testing first appeared in the medical literature in 1938. Since then, exercise testing has achieved an established place in the armamentarium of tests available to the physician for evaluating patients with known or suspected cardiac disease. In clinical practice, the application of exercise testing is often combined with cardiac imaging. This is reflected in recently available appropriate use criteria for myocardial perfusion imaging and stress echocardiography.2'3 However, exercise testing as a standalone test without imaging still has value in properly selected patients. The latest iteration of guidelines from the American College of Cardiology/American Heart Association (ACC/AHA) concerning exercise testing is dominated by diagnostic or prognostic assessments of atherosclerotic coronary artery disease applications.4 Less prominent are those applications that pertain to hypertrophic cardiomyopathy (HCM), valvular heart disease, and arrhythmias including pacemakers, all of which are the subject of this review.